Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7195818 | 0.83 | CA1 (0.32) | CA1CA2 | |
| SCHEMBL30584471 | 0.80 | CA12 (0.41) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL7333093 | 0.80 | CA12 (0.41) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL6745352 | 0.79 | ABCB1 (0.45) | TAAR1SIGMAR1HRH3ABCB1 | |
| SCHEMBL6909824 | 0.77 | DAO (0.31) | — | |
| SCHEMBL28858018 | 0.76 | TAAR1 (0.75) | TAAR1SIGMAR1KCNH2HRH3ABCB1 | |
| SCHEMBL6913106 | 0.74 | LIPG (0.35) | ALDH1A1 | |
| SCHEMBL6745345 | 0.74 | CA1 (0.36) | IDO1ALDH1A1CA12CA1CA2 | |
| SCHEMBL5698313 | 0.74 | TDP1 (0.30) | — | |
| SCHEMBL27506183 | 0.74 | TAAR1 (0.40) | TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063951-A1 | Alkaloid halide salts of swainsonine and methods of use | GLYCODESIGN HOLDINGS LTD. (CA) | 2004-04-01 | — | — | US | disclosed |
| US-20030105326-A1 | Alkaloid halide salts of swainsonine and methods of use | DENNIS JAMES W (CA) | 2003-06-05 | — | — | US | disclosed |
| EP-1264832-A1 | Alkaloid halide salts of swainsonine and methods of use | Glycodesign Inc. (CA) | 2002-12-11 | — | — | EP | disclosed |
| EP-0975632-B1 | ALKALOID HALIDE SALTS OF SWAINSONINE AND METHODS OF USE | GLYCODESIGN INC (CA) | 2002-10-16 | — | — | EP | disclosed |
| US-6395745-B1 | STABLE, CRYSTAL STRUCTURE; PLANT EXTRACT | GLYCODESIGN, INC. (CA) | 2002-05-28 | — | — | US | disclosed |
| EP-0975632-A1 | ALKALOID HALIDE SALTS OF SWAINSONINE AND METHODS OF USE | Glycodesign Inc. (CA) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998046602-A1 | ALKALOID HALIDE SALTS OF SWAINSONINE AND METHODS OF USE | GLYCODESIGN INC. (CA) | 1998-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105326-A1 | Alkaloid halide salts of swainsonine and methods of use | SLC6A12, PWWP2B, WNK2 | TAAR1 1112/4885SIGMAR1 994/4885KCNH2 139/4885 |
| US-20040063951-A1 | Alkaloid halide salts of swainsonine and methods of use | SLC6A12, TUBB3, HNMT | TAAR1 733/4885SIGMAR1 851/4885KCNH2 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.